Skip to main content
SpringerLink
Log in

Meta‐analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Meta‐analysis of all clinical data was conducted to compare toremifene 40–60 mg/day (TOR) with tamoxifen 20–40 mg/day (TAM) in postmenopausal women with estrogen receptor (ER) positive or ER unknown advanced breast cancer and assess factors predicting treatment outcome. Data from five randomized parallel group studies (all studies) were combined. Efficacy variables were the response rate in all studies and also the time to treatment failure and survival in the three major studies (pivotal studies).

Of the 1421 patients, 725 received TOR and 696 TAM. Response rates were 24.0 and 25.3, respectively (p=0.675) with 95 confidence interval (95 CI) for the difference −5.3 to 3.4. Of the 1157 patients in the pivotal studies, 75 had progressed and 50 expired. Median treatment times were 4.9 months in TOR and 5.3 months in TAM groups (p=0.762, hazard ratio 0.98 with 95 CI 0.87–1.11). Median survival times were 31.0 (TOR) and 33.1 (TAM) months (p=0.758, hazard ratio 0.98 with 95 CI 0.83–1.15). All results are consistent with the criteria of statistical equivalence between TOR and TAM. More patients in TAM (20) than in TOR (14, p=0.007) discontinued the treatment prematurely but overall the treatments were well tolerated. As the treatments were equally effective all data were analyzed together for predictive factors. High tumor ER concentration, long disease free time, soft tissue metastases, few metastatic sites, and good performance status all independently predicted longer survival (p<0.001). Previous adjuvant tamoxifen predicted shorter survival (p=0.008). Objective response to treatment or disease stabilization for at least 12 months both predicted prolonged survival (p=0.001).

TOR 60 mg/day and TAM are equally effective and well tolerated in the treatment of advanced breast cancer in postmenopausal women. Probability of survival may be predicted based on patient characteristics and on the initial response to the treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jaiyesimi IA, Buzdar AU, Decker DA and Hortobagyi GN: Use of tamoxifen for breast cancer: Twenty-eight years later. J Clin Oncol 13: 513–529, 1995

    Google Scholar 

  2. Osborne CK: Receptors, In: Harris J, Hellman S, Henderson I et al. (eds) Breast Diseases. Lippincott, Philadelphia, PA, 1991, pp 301–325

    Google Scholar 

  3. Henderson IC: Endocrine therapy of metastatic breast cancer. In: Harris JR, Hellman S, Henderson IC et al. (eds) Breast Diseases. Lippincott, Philadelphia, PA, 1991, pp 559–603

    Google Scholar 

  4. Early breast cancer trialists collaborative group: Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339: 1–15, 1992

    Google Scholar 

  5. Goldhirsch A, Wood WC, Senn H-J et al.: Meeting highlights: International consensus panel on the treatment of primary breast cancer. J Natl Cancer Instit 87: 1441–1445, 1995

    Google Scholar 

  6. Love RR: Prospects for antiestrogen chemoprevention of breast cancer. J Natl Cancer Inst 82: 18–22, 1990

    Google Scholar 

  7. Powles TJ, Hardy JK, Ashley SE et al.: A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for preventing breast cancer. Br J Cancer 60: 126–131, 1990

    Google Scholar 

  8. Kangas L, Kallio S, Blanco G, Grönroos M, Kallio S, Karjalainen A, Perilä M, Södervall M, Toivola R: A new triphenylethylene compound, FC-1157a. II. Antitumor effects. Cancer Chemother Pharmacol 17: 109–114, 1986

    Google Scholar 

  9. Kangas L: Agonistic and antagonistic effects of antiestrogens in different target organs. Acta Oncol 31: 143–146, 1992

    Google Scholar 

  10. di Salle E, Zaccheo T, Ornati G: Antiestrogenic and antitumor properties of the new triphenylethylene derivative toremifene in the rat. J Steroid Biochem 36: 203–206, 1990

    Google Scholar 

  11. IARC monographs on the evaluation on the carcinogenic risk to humans. Some Pharmaceutical Drugs. IARC Press Lyon, France 66, 1996

  12. Saarto T, Blomqvist C, Välimäki M et al.: Clodronate improves bone mineral density in postmenopausal breast cancer patients treated with adjuvant antiestrogens. Br J Cancer 75: 602–605, 1997

    Google Scholar 

  13. Saarto T, Blomqvist C, Ehnholm C et al.: Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with nodepositive breast cancer. J Clin Oncol 14: 429–433, 1996

    Google Scholar 

  14. Jordan VC, Dix CJ, Naylor KE, Prestwitch G, Rowsby L: Nonsteroidal antiestrogens: their biological effects and potential mechanism of action. J Toxicol Environ Health 4: 363–390, 1978

    Google Scholar 

  15. Wärri AM, Huovinen RL, Laine AM et al.: Apoptosis in toremifene-induced growth inhibition of human breast cancer cells in vivo and in vitro. J Natl Cancer Inst 85: 1412–1418, 1993

    Google Scholar 

  16. Lahti EI, Knip M, Laatikainen TJ: Plasma insulin-like growth factor I and its binding proteins 1 and 3 in postmenopausal patients with breast cancer receiving long term tamoxifen. Cancer 74: 618–624, 1994

    Google Scholar 

  17. Rankumar T, Adler S: Differential positive and negative transcriptional regulation by tamoxifen. Endocrinol 136: 536–542, 1995

    Google Scholar 

  18. Wiseman H: Tamoxifen: new membrane-mediated mechanisms of action and therapeutic advances. TIPS 15: 83–89, 1994

    Google Scholar 

  19. Su H-D, Mazzei GJ, Vogler WR, Kuo JF: Effect of tamoxifen, a nonsteroidal antiestrogen, on phospholipid/Calciumdependent protein kinase and phosphorylation of its endogenous substrate proteins from the rat brain and ovary. Biochem Pharmacol 34: 3649–3653, 1985

    Google Scholar 

  20. Valverde MA, Mintenig GM, SepÚlveda FV: Differential effects of tamoxifen and I on three distinguishable chloride currents activated in T84 intestinal cells. Eur J Physiol 425: 552–554, 1993

    Google Scholar 

  21. DeGregorio M, Ford JM, Benz CC, Wiebe VJ: Toremifene: pharmacological and pharmacokinetic basis of reversing multidrug resistance. J Clin Oncol 7: 1359–1364, 1989

    Google Scholar 

  22. Chatterjee M, Harris AL: Enhancement of adriamycin cytotoxicity in a multidrug resistant chinese hamster ovary (CHO) subline, CHO-Adrr, by toremifene and its modulation by alpha1 acid glycoprotein. Eur J Cancer 26: 432–436, 1990

    Google Scholar 

  23. Ahotupa M, Hirsimäki P, Hirsimäki Y, Pärssinen R, Mäntylä E: Alterations of drug metabolizing and antioxidant enzyme activities during tamoxifen-induced hepatocarcinogenesis in the rat. Carcinogenesis 15: 863–868, 1994

    Google Scholar 

  24. Thangaraju M, Ezhilarasi R, Sachdanandam P: Effect of tamoxifen on erythrocyte membrane lipids, lipid peroxides, and antioxidative enzymes in breast cancer women. Cancer Biochem Biophys 14: 297–302, 1995

    Google Scholar 

  25. Kendall ME, Rose DP: The effects of diethylstilbesterol, tamoxifen, and toremifene on estrogen-inducible hepatic proteins and estrogen receptor proteins in female rats. Toxicol Appl Pharmacol 114: 127–131, 1992

    Google Scholar 

  26. Számel I, Hindy I, Vincze B et al.: Influence of toremifene on the endocrine regulation in breast cancer patients. Eur J Cancer 30A: 154–158, 1994

    Google Scholar 

  27. Robinson SP, Jordan VC: Antiestrogenic action of toremifene on hormone-dependent,-independent, and heterogenous breast tumor growth in the athymic mouse. Cancer Res 49: 1758–1762, 1989

    Google Scholar 

  28. Moon RC, Steele VE, Kelloff GJ, Thomas CF, Detrisac CJ, Mehta RG, Lubet RA: Chemoprevention of MNU-induced mammary tumorigenesis by hormone response modifiers: toremifene, RU 16117, tamoxifen, aminoglutethimide and progesterone. Anticancer Res 14: 889–894, 1994

    Google Scholar 

  29. Valavaara R, Pyrhönen S, Heikkinen M, Rissanen P, Blanco G, Thölix E, Nordman E, Taskinen P, Holsti L, Hajba A: Toremifene, a new antiestrogenic compound, for treatment of advanced breast cancer. Phase II study. Eur J Cancer Clin Oncol 24: 785–790, 1988

    Google Scholar 

  30. Pyrhönen S, Valavaara R, Heikkinen M, Rissanen P, Blanco G, Nordman E, Holsti RL, Hajba A: Treatment of advanced breast cancer with 20 mg toremifene, a phase II study. Preliminary communication. J Steroid Biochem 36: 227–228, 1990

    Google Scholar 

  31. Hietanen T, Baltina D, Johansson R et al.: High dose toremifene (240 mg daily) is effective as first line hormonal treatment in advanced breast cancer - An ongoing phase II multicenter Finnish-Latvian cooperative study. Breast Cancer Res Treat 16: 37–40, 1990

    Google Scholar 

  32. Stenbygaard LE, Herrstedt J, Thomsen JF, Svendsen KR, Engelholm SAA, Dombernowsky P: Toremifene and tamoxifen in advanced breast cancer - a double-blind cross-over trial. Breast Cancer Res Treat 25: 57–63, 1993

    Google Scholar 

  33. Hayes DF, van Zyl JA, Hacking A et al.: Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol 13: 2556–2566, 1995

    Google Scholar 

  34. Pyrhönen S, Valavaara R, Modig H, Pawlicki M, Pienkowski T, Gundersen S, Bauer J, Westman G, Lundgren S, Blanco G, Mella O, Nilsson I, Hietanen T, Hindy I, Vuorinen J, Hajba A: Comparison of toremifene and tamoxifen in postmenopausal patients with advanced breast cancer: a randomised double blind, the 'Nordic' phase III study. Br J Cancer 76: 270–277, 1997

    Google Scholar 

  35. Gershanovich M, Garin A, Baltina D, Kurvet A, Kangas L, Ellmén J: A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer. Breast Cancer Res Treat 45: 251–262, 1997.

    Google Scholar 

  36. Kaufmann M, Sindermann H, Burk K, Hilgard P: Multicentric phase II trial of efficacy and tolerance of toremifene (FC-1157a) in patients with hormonally pretreated advanced breast cancer. Orion Corporation, Orion Pharma study report 5/032, 22.2.1993

  37. Nomura Y, Tominaga T, Abe O, Izuo M, Ogawa N. Clinical evaluation of NK 622 (toremifene citrate) in advanced or recurrent breast cancer - a comparative study by a double blind method with tamoxifen. Jpn J Cancer Chemother 20: 247–258, 1993

    Google Scholar 

  38. Miller AB, Hoogstarten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47: 207–214, 1981

    Google Scholar 

  39. Oyen MM, Greech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP: Toxicity and response criteria of Eastern Cooperative Oncology Group. AM J Oncol 5: 649–655, 1982

    Google Scholar 

  40. Kinbara Shuppan (ed): General Rules for Clinical and Pathological Recordings of Breast Cancer, 9th edn. Japanese Breast Cancer Society, Tokyo, 1988 (in Japanese)

    Google Scholar 

  41. WHO Adverse Reaction Dictionary: WHO collaborating center for international drug monitoring, Uppsala, Sweden. March 1988

  42. Whitehead A, Whitehead J: A general parametric approach to the meta-analysis of randomized clinical trials. Statistics in Medicine 10: 1665–1677, 1991

    Google Scholar 

  43. Bratherton DG, Brown CH, Buchanan R et al.: A comparison of two doses of tamoxifen (Nolvadex_) in postmenopausal women with advanced breast cancer: 10 mg bd versus 20 mg bd. Br J Cancer 50: 199–205, 1984

    Google Scholar 

  44. Mouridsen H, Palshof T, Patterson J, Battersby L: Tamoxifen in advanced breast cancer. Cancer Treat Rev 5: 131–141, 1978

    Google Scholar 

  45. Homesley HD, Shemano I, Gams R et al.: Antiestrogenic potency of toremifene and tamoxifen in postmenopausal women. Am J Clin Oncol 16: 117–122, 1993

    Google Scholar 

  46. Kendall ME, Rose DP: The effects of diethylstilbestrol, tamoxifen, and toremifene on estrogen-iducible hepatic proteins and estrogen receptor proteins in female rats. Toxicol Appl Pharmacol 114: 127–131, 1992

    Google Scholar 

  47. Kuukasjärvi T, Kononen J, Helin H, Holli K, Isola J: Loss of estrogen receptor in recurrent breast cancer associated with poor response to endocrine therapy. J Clin Oncol 14: 2584–2589, 1996

    Google Scholar 

  48. Legler CM, Shemano I, Schoenfelder J, Hayes DF. Effect of prior tamoxifen (TAM) on response to TAM & toremifene (TOR) in metastatic breast cancer. Proc Am Soc Clin Oncol 14: 91a, 1995 (abstr)

    Google Scholar 

  49. Howell A, Mackintosh I, Jones M, Redford J, Wagstaff J, Sellwood RA: The definition of the 'No Change' category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast. Eur J Cancer Clin Onc 24: 1567–1572, 1988

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology and Radiotherapy, Turku University Central Hospital, Turku, Finland

    S. Pyrhönen

  2. Oncology, Orion Corporation, Orion Pharma, Clinical R & D, Turku, Finland

    J. Ellmén

  3. Biostatistics, Orion Corporation, Orion Pharma, Turku, Finland

    J. Vuorinen

  4. N.N. Petrov Research Institute of Oncology, St. Petersburg, Russia

    M. Gershanovich

  5. Tokyo Metropolitan Komagome Hospital, Tokyo, Japan

    T. Tominaga

  6. Universitäts‐Frauenklinik, Frankfurt am Main, Germany

    M. Kaufmann

  7. Lombardi Cancer Center, Room E504, Research Building, NW, Washington, DC, USA

    D.F. Hayes

Authors
  1. S. Pyrhönen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Ellmén
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Vuorinen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Gershanovich
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T. Tominaga
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Kaufmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. D.F. Hayes
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pyrhönen, S., Ellmén, J., Vuorinen, J. et al. Meta‐analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer. Breast Cancer Res Treat 56, 131–141 (1999). https://doi.org/10.1023/A:1006250213357

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006250213357

Search

Navigation